EM De Francesco
Vitamin C and Doxycycline : a synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs)
De Francesco, EM; Bonuccelli, G; Maggiolini, M; Sotgia, F; Lisanti, MP
Authors
G Bonuccelli
M Maggiolini
Prof Federica Sotgia F.Sotgia@salford.ac.uk
Honorary Staff
Prof Michael Lisanti M.P.Lisanti@salford.ac.uk
Honorary Staff
Abstract
Here, we developed a new synthetic lethal strategy for further optimizing the eradication of cancer stem cells (CSCs). Briefly, we show that chronic treatment with the FDA-approved antibiotic Doxycycline effectively reduces cellular respiration, by targeting mitochondrial protein translation. The expression of four mitochondrial DNA encoded proteins (MT-ND3, MT-CO2, MT-ATP6 and MT-ATP8) is suppressed, by up to 35-fold. This high selection pressure metabolically synchronizes the surviving cancer cell sub-population towards a predominantly glycolytic phenotype, resulting in metabolic inflexibility. We directly validated this Doxycycline-induced glycolytic phenotype, by using metabolic flux analysis and label-free unbiased proteomics.
Next, we identified two natural products (Vitamin C and Berberine) and six clinically-approved drugs, for metabolically targeting the Doxycycline-resistant CSC population (Atovaquone, Irinotecan, Sorafenib, Niclosamide, Chloroquine, and Stiripentol). This new combination strategy allows for the more efficacious eradication of CSCs with Doxycycline, and provides a simple pragmatic solution to the possible development of Doxycycline-resistance in cancer cells. In summary, we propose the combined use of i) Doxycycline (Hit-1: targeting mitochondria) and ii) Vitamin C (Hit-2: targeting glycolysis), which represents a new synthetic-lethal metabolic strategy for eradicating CSCs.
This type of metabolic Achilles' heel will allow us and others to more effectively “starve” the CSC population.
Journal Article Type | Article |
---|---|
Acceptance Date | May 17, 2017 |
Online Publication Date | Jun 9, 2017 |
Publication Date | Jun 9, 2017 |
Deposit Date | Jul 12, 2017 |
Publicly Available Date | Jul 12, 2017 |
Journal | Oncotarget |
Electronic ISSN | 1949-2553 |
Publisher | Impact Journals |
Volume | 2017 |
Issue | 8 |
Pages | 67269-67286 |
DOI | https://doi.org/10.18632/oncotarget.18428 |
Publisher URL | http://dx.doi.org/10.18632/oncotarget.18428 |
Related Public URLs | http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=index |
Files
18428-268964-2-PB (1).pdf
(4.4 Mb)
PDF
Licence
http://creativecommons.org/licenses/by/3.0/
Publisher Licence URL
http://creativecommons.org/licenses/by/3.0/